ASCO 2023 is just around the corner and we are teaming up with The Fellow On Call to bring you a joint mini-series called “Paging Heme/Onc: Updates from ASCO 2023” where we’ll bring you brief, high-yield discussions of some of the research we found most interesting from this year’s conference.

Paging Heme/Onc: Updates from ASCO 2023

This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational resource for health care providers.*

Medicine

Science & Medicine

Health & Fitness

This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam. 


ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC

Today’s episode is updating what you need to know regarding the treatment of metastatic melanoma. We are so honored to have Dr. Michael Atkins here with us today, who is the first author of the practice changing DREAMseq trial, and provides his expertise on this important topic.

Metastatic Melanoma 2024 x Dr. Mike Atkins Part 2

Today’s episode is a 2024 update on what to know regarding the risk factors, diagnostic work-up, staging and treatment of localized melanoma. We are so honored to have Dr. Michael Atkins here with us today who is deputy director of the Georgetown Lombardi Comprehensive Cancer Center . He is an internationally recognized expert in the management of patients with high-risk and metastatic melanoma or kidney cancer. 

Localized Melanoma 2024 x Dr. Mike Atkins Part 1

This week’s episode will be focusing on the second part of genetic syndromes with risk of malignancy. Last week we covered Li Fraumeni, Lynch, FAP, BRCA ½ and Cowdens. This week we are going to cover the syndromes associated with RCC as well as MEN 1 and 2 and a few others. 

Genetic Syndromes Part 2

This week’s episode will be focusing on genetic syndromes with increased risk of malignancies. In Part 1 we discuss Li-Fraumeni, Lynch Syndrome, FAP, BRCA 1 and 2, and Cowden's syndrome. 


Paging Heme/Onc: Updates from ASCO 2023

Download our free app to listen on your phone